Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-α transgenic mice

Journal of Immunology

Volumn 175, Issue 12, 2005, Pages 8327-8336

  Hayer, Silvia ^a   Tohidast Akrad, Makiyeh ^b   Haralambous, Silva ^c   Jahn Schmid, Beatrice ^a   Skriner, Karl ^a,h   Trembleau, Sylvie ^d   Dumortier, Hélène ^e   Pinol Roma, Serafin ^f   Redlich, Kurt ^a   Schett, Georg ^a   Muller, Sylviane ^e   Kollias, George ^g   Smolen, Josef ^a,b,d   Steiner, Günter ^a,b,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e CNRS   (France)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; HEAT SHOCK PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BRAIN; CONTROLLED STUDY; INFLAMMATION; JOINT; JOINT DESTRUCTION; LUNG; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPLEEN; THYMUS; TRANSGENIC MOUSE;

EID: 29144516274     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.12.8327     Document Type: Article

References (74)

1. Feldmann, M., and R. N. Maini. 2003. Lasker Clinical Medical Research Award: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9: 1245-1250.
2. Weyand, C. M. 2000. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 39(Suppl. 1): 3-8.
3. Kremer, J. M., R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, A. Russell, M. Dougados, P. Emery, I. F. Nuamah, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349: 1907-1915.
4. Smolen, J. S., S. Hayer, G. Schett, K. Redlich, M. Aringer, G. Kollias, E. Wagner, and G. Steiner. 2004. Autoimmunity and rheumatoid arthritis. Autoimmun. Rev. 3(Suppl. 1): S23.
5. Steiner, G., and J. Smolen. 2002. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4(Suppl 2): S1-S5.
6. Doyle, H. A., and M. J. Mamula. 2001. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 22: 443-449.
7. Vossenaar, E. R., and W. J. van Venrooij. 2004. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther. 6: 107-111.
8. Hassfeld, W., G. Steiner, A. Studnicka Benke, K. Skriner, W. Graninger, I. Fischer, and J. S. Smolen. 1995. Autoimmune response to the spliceosome: an immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 38: 777-785.
9. Steiner, G., K. Skriner, and J. S. Smolen. 1996. Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int. Arch. Allergy Immunol. 111: 314-319.
10. Fritsch, R., D. Eselbock, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. Tohidast-Akrad, S. Hayer, J. Neumuller, S. Pinol-Roma, et al. 2002. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J. Immunol. 169: 1068-1076.
11. Rantapaa-Dahlqvist, S., B. A. de Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, U. Sundin, and W. J. van Venrooij. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48: 2741-2749.
12. Nielen, M. M. J., D. van Schaardenburg, H. W. R. Reesink, R. J. van de Stadt, I. E. van der Horst-Bruinsma, M. H. de Koning, M. R. Habibuw, J. P. Vandenbroucke, and B. A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380-386.
13. Kollias, G., E. Douni, G. Kassiotis, and D. Kontoyiannis. 1999. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 169: 175-194.
14. Kyburz, D., and M. Corr. 2003. The KRN mouse model of inflammatory arthritis. Springer Semin. Immunopathol. 25: 79-90.
15. Monach, P. A., C. Benoist, and D. Mathis. 2004. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv. Immunol. 82: 217-248.
16. Redlich, K., S. Hayer, R. Ricci, J. P. David, M. Tohidast Akrad, G. Kollias, G. Steiner, J. S. Smolen, E. F. Wagner, and G. Schett. 2002. Osteoclasts are essential for TNF-α-mediated joint destruction, J. Clin. Invest. 110: 1419-1427.
17. Zwerina, J., S. Hayer, M. Tohidast Akrad, H. Bergmeister, K. Redlich, U. Feige, C. Dunstan, G. Kollias, G. Steiner, J. Smolen, and G. Schett. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50: 277-290.
18. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031.
19. Georgopoulos, S., D. Plows, and G. Kollias. 1996. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 46: 86-97.
20. Redlich, K., S. Hayer, A. Maier, C. R. Dunstan, M. Tohidast Akrad, S. Lang, B. Turk, P. Pietschmann, W. Woloszczuk, S. Haralambous, et al. 2002. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46: 785-792.
21. Marcu, A., B. Bassit, R. Perez, and S. Pinol-Roma. 2001. Heterogeneous nuclear ribonucleoprotein complexes from Xenopus laevis oocytes and somatic cells. Int. J. Dev. Biol. 45: 743-752.
22. Skriner, K., W. H. Sommergruber, V. Tremmel, I. Fischer, A. Barta, J. S. Smolen, and G. Steiner. 1997. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex: differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J. Clin. Invest. 100: 127-135.
23. Dumortier, H., F. Monneaux, B. Jahn Schmid, J. P, Briand, K. Skriner, P. L. Cohen, J. S. Smolen, G. Steiner, and S. Muller. 2000. B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J. Immunol. 165: 2297-2305.
24. Schreiber, E., P. Matthias, M. M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucleic Acids Res. 17: 6419.
25. Swanson, M. S., and G. Dreyfuss. 1988. RNA binding specificity of hnRNP proteins: a subset binds to the 3′ end of introns. EMBO J. 7: 3519-3529.
26. Habets, W. J., M. H. Hoet, B. A. De Jong, A. Van der Kemp, and W. J. van Venrooij. 1989. Mapping of B cell epitopes on small nuclear ribonucleoproteins that react with human autoantibodies as well as with experimentally-induced mouse monoclonal antibodies. J. Immunol. 143: 2560-2566.
27. van Eekelen, C. A., M. H. Salden, W. J. Habets, L. B. van de Putte, and W. J. van Venrooij. 1982. On the existence of an internal nuclear protein structure in HeLa cells. Exp. Cell Res. 141: 181-190.
28. Ma, A. S., K. Moran Jones, J. Shan, T. P. Munro, M. J. Snee, K. S. Hoek, and R. Smith. 2002. Heterogeneous nuclear ribonucleoprotein A3, a novel RNA trafficking response element-binding protein. J. Biol. Chem. 277: 18010-18020.
29. Burd, C. G., M. S. Swanson, M. Gorlach, and G. Dreyfuss. 1989. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc. Natl. Acad. Sci. USA 86: 9788-9792.
30. Cope, A. P., R. S. Liblau, X. D. Yang, M. Congia, C. Laudanna, R. D. Schreiber, L. Probert, G. Kollias, and H. O. McDevitt. 1997. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185: 1573-1584.
31. Hatfield, J. T., J. A. Rothnagel, and R. Smith. 2002. Characterization of the mouse hnRNP A2/B1/B0 gene and identification of processed pseudogenes. Gene 295: 33-42.
32. Krecic, A. M., and M. S. Swanson. 1999. hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol. 11: 363-371.
33. Hietarinta, M., and O. Lassila. 1996. Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Ann. Med. 28: 283-291.
34. von Muhlen, C. A., and E. M. Tan. 1995. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum. 24: 323-358.
35. Smolen, J. S., and G. Steiner. 1998. Are autoantibodies active players or epiphenomena? Curr. Opin. Rheumatol 10: 201-206.
36. Masson-Bessiere. C., M. Sebbag, E. Girbal-Neuhauser, L. Nogueira, C. Vincent, T. Senshu, and G. Serre. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J. Immunol. 166: 4177-4184.
37. Bas, S., S. Genevay, O. Meyer, and C. Gabay. 2003. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42: 677-680.
38. La Cava, A., C. Fine, E. Rodriguez, A. Ilic, N. Sarvetnick, and M. S. Horwitz. 2000. Viruses, host responses, and autoimmunity. Nat Med. 6: 693-697.
39. Smolen, J. S., and G. Steiner. 2001. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum. 44: 2218-2220.
40. Fournie, G. J., M. Mas, B. Cautain, M. Savignac, J. F. Subra, L. Pelletier, A. Saoudi, D. Lagrange, M. Calise, and P. Druet. 2001. Induction of autoimmunity through bystander effects: lessons from immunological disorders induced by heavy metals. J. Autoimmun. 16: 319-326.
41. Mathis, D., L. Vence, and C. Benoist. 2001. β-Cell death during progression to diabetes. Nature 414: 792-798.
42. Maier, B., L. Morawietz, V. Krenn, T. Kamradt, and F. J. Descamps. 2004. Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes. J. Immunol. 172: 4503-4509.
43. Green, E. A., and R. A. Flavell. 2000. The temporal importance of TNFα expression in the development of diabetes. Immunity 12: 459-469.
44. Klein, L., M. Klugmann, K. A. Nave, V. K. Tuohy, and B. Kyewski. 2000. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat. Med. 6: 56-61.
45. 1 hybrids. J. Autoimmun. 4; 595-606.
46. Lanzavecchia, A. 1995. How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181: 1945-1948.
47. Maki, M. 1996. Coeliac disease and autoimmunity due to unmasking of cryptic epitopes? Lancet 348: 1046-1047.
48. Lan, M. S., and N. K. Maclaren. 1998. Cryptic epitope and autoimmunity. Diabetes Metab. Rev. 14: 333-334.
49. Olson, J. K., J. L. Croxford, and S. D. Miller. 2001. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol. 14: 227-250.
50. Visan, L., I. A. Visan, A. Weishaupt, H. H. Hofstetter, K. V. Toyka, T. Hunig, and R. Gold. 2004. Tolerance induction by intrathymic expression of P0. J. Immunol. 172: 1364-1370.
51. Nichols, R. C., X. W. Wang, J. Tang, B. J. Hamilton, F. A. High, H. R. Herschman, and W. F. Rigby. 2000. The RGG domain in hnRNP A2 affects subcellular localization. Exp. Cell Res. 256: 522-532.
52. Prakken, B. J., S. Roord, A. Ronaghy, M. Wauben, S. Albani, and W. van Eden. 2003. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin. Immunopathol. 25: 47-63.
53. van Eden, W., R. van der Zee, and B. Prakken. 2005. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat. Rev. Immunol. 5: 318-330.
54. Panayi, G., and V. Corrigall. 2004. BiP: a new biologic immunomodulator for the treatment of rheumatoid arthritis. Autoimmun. Rev. 3(Suppl 1): S16-S17.
55. de Graeff-Meeder, E. R., M. Voorhorst, W. van Eden, H. J. Schuurman, J. Huber, D. Barkley, R. N. Maini, W. Kuis, G. T. Rijkers, and B. J. Zegers. 1990. Antibodies to the mycobacterial 65-kd heat-shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis. Am. J. Pathol 137: 1013-1017.
56. Barker, R. N., A. D. Wells, M. Ghoraishian, A. J. Easterfield, Y. Hitsumoto, C. J. Elson, and S. J. Thompson. 1996. Expression of mammalian 60-kD heat shock protein in the joints of mice with pristane-induced arthritis. Clin. Exp. Immunol. 103: 83-88.
57. Schett, G., K. Redlich, Q. Xu, P. Bizan, M. Groger, M. Tohidast-Akrad, H. Kiener, J. Smolen, and G. Steiner. 1998. Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue: differential regulation of hsp70 expression and hsf 1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J. Clin. Invest. 102: 302-311.
58. Kindas Mugge, I., G. Steiner, and J. S. Smolen. 1993. Similar frequency of autoantibodies against 70-kD class heat-shock proteins in healthy subjects and systemic lupus erythematosus patients. Clin. Exp. Immunol. 92: 46-50.
59. Zugel, U., and S. H. Kaufmann. 1999. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin. Microbiol. Rev. 12: 19-39.
60. Kim, H. 2003. Diagnostic significance of antibodies to heat shock proteins. Clin. Chim. Acta 337: 1-10.
61. Prakken, B., W. Kuis, W. van Eden, and S. Albani. 2002. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr. Rheumatol Rep. 4: 466-473.
62. Vossenaar, E. R., S. Nijenhuis, M. M. Helsen, A. van der Heijden, T. Senshu, W. B. van den Berg, W. J. van Venrooij, and L. A. Joosten. 2003. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 48: 2489-2500.
63. Vossenaar, E. R., M. A. van Boekel, W. J. van Venrooij, M. Lopez-Hoyoz, J. Merino, R. Merino, and L. A. Joosten. 2004. Absence of citrulline-specific autoantibodies in animal models of autoimmuntty. Arthritis Rheum. 50: 2370-2372.
64. van Gaalen, F. A., J. van Aken, T. W. Huizinga, G. M. Schreuder, F. C. Breedveld, E. Zanelli, W. J. van Venrooij, C. L. Verweij, R. E. Toes, and R. R. de Vries. 2004. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50: 2113-2121.
65. Hoffman, I. E., I. Peene, H. Pottel, A. Union, F. Hulstaert, L. Meheus, K. Lebeer, L. De Clercq, L. Schatteman, S. Poriau, et al. 2005. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin. Chem. 51: 261-263.
66. Hassfeld, W., G. Steiner, W. Graninger, G. Witzmann, H. Schweitzer, and J. S. Smolen. 1993. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br. J. Rheumatol. 32: 199-203.
67. Nell, V., K. P. Machold, T. A. Stamm, G. Eberl, H. Heinzl, M. Uffmann, J. S. Smolen, and G. Steiner. 2005, Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann. Rheum. Dis. 64: 1731-1736.
68. Mayeda, A., S. H. Munroe, J. F. Caceres, and A. R. Krainer. 1994. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13: 5483-5495.
69. Kamma, H., M. Fujimoto, M. Fujiwara, M. Matsui, H. Horiguchi, M. Hamasaki, and H. Satoh. 2001. Interaction of hnRNP A2/B1 isoforms with telomeric ssDNA and the in vitro function. Biochem. Biophys. Res. Commun. 280: 625-630.
70. Brumwell, C., C. Antolik, J. H. Carson, and E. Barbarese. 2002. Intracellular trafficking of hnRNP A2 in oligodendrocytes. Exp. Cell Res. 279: 310-320.
71. Matsui, M., H. Horiguchi, H. Kamma, M. Fujiwara, R. Ohtsubo, and T. Ogata. 2000. Testis- and developmental stage-specific expression of hnRNP A2/B1 splicing isoforms, B0a/b. Biochim. Biophys. Acta 1493: 33-40.
72. Zhou, J., J. L. Mulshine, E. J. Unsworth, F. M. Scott, I. M. Avis, M. D. Vos, and A. M. Treston. 1996. Purification and characterization of a protein that permits early detection of lung cancer: identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J. Biol. Chem. 271: 10760-10766.
73. Tani, H., K. Ohshima, S. Haraoka, M. Hamasaki, H. Kamma, S. Ikeda, and M. Kikuchi. 2002. Overexpression of heterogeneous nuclear ribonucleoprotein B1 in lymphoproliferative disorders: high expression in cells of follicular center origin. Int. J. Oncol. 21: 957-963.
74. Pino, I., R. Pio, G. Toledo, N. Zabalegui, S. Vicent, N. Rey, M. D. Lozano, W. Torre, J. Garcia-Foncillas, and L. M. Montuenga. 2003. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41: 131-143.